Access the full text.
Sign up today, get DeepDyve free for 14 days.
Kengo Suzuki, Y. Akashi, Mariko Manabe, K. Mizukoshi, Ryo Kamijima, S. Kou, Manabu Takai, M. Izumo, K. Kida, K. Yoneyama, K. Omiya, Y. Yamasaki, H. Yamada, S. Nobuoka, F. Miyake (2013)
Simple exercise echocardiography using a Master's two-step test for early detection of pulmonary arterial hypertension.Journal of cardiology, 62 3
Y. Shirai, H. Yasuoka, Y. Okano, T. Takeuchi, T. Satoh, M. Kuwana (2012)
Clinical characteristics and survival of Japanese patients with connective tissue disease and pulmonary arterial hypertension: a single-centre cohort.Rheumatology, 51 10
R. Califf, K. Adams, W. McKenna, M. Gheorghiade, B. Uretsky, S. McNulty, H. Darius, K. Schulman, F. Zannad, E. Handberg-Thurmond, F. Harrell, William Wheeler, J. Soler‐Soler, K. Swedberg (1997)
A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST).American heart journal, 134 1
G. Kovacs, A. Avian, M. Tscherner, V. Foris, G. Bachmaier, A. Olschewski, H. Olschewski (2014)
Characterization of patients with borderline pulmonary arterial pressure.Chest, 146 6
G. Simonneau, M. Gatzoulis, M. Gatzoulis, I. Adatia, I. Adatia, D. Celermajer, D. Celermajer, C. Denton, A. Ghofrani, M. Sánchez, R. Kumar, M. Landzberg, R. Machado, H. Olschewski, I. Robbins, Rogiero Souza (2009)
Updated clinical classification of pulmonary hypertension.Journal of the American College of Cardiology, 62 25 Suppl
R. Condliffe, D. Kiely, A. Peacock, P. Corris, J. Gibbs, F. Vrapi, C. Das, C. Elliot, Martin Johnson, J. Desoyza, Chantal Torpy, K. Goldsmith, D. Hodgkins, Rodney Hughes, J. Pepke-Zaba, J. Coghlan (2009)
Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era.American journal of respiratory and critical care medicine, 179 2
R. Kasukawa (1987)
Preliminary diagnostic criteria for classification of mixed connective tissue disease
K. Kuhn, Daniel Byrne, P. Arbogast, T. Doyle, J. Loyd, I. Robbins (2003)
Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol.American journal of respiratory and critical care medicine, 167 4
C. Valerio, B. Schreiber, C. Handler, C. Denton, J. Coghlan (2013)
Borderline mean pulmonary artery pressure in patients with systemic sclerosis: transpulmonary gradient predicts risk of developing pulmonary hypertension.Arthritis and rheumatism, 65 4
E. Lau, A. Manes, D. Celermajer, N. Galiè (2011)
Early detection of pulmonary vascular disease in pulmonary arterial hypertension: time to move forward.European heart journal, 32 20
B. Fox, A. Shimony, D. Langleben, A. Hirsch, L. Rudski, R. Schlesinger, M. Eisenberg, Dominique Joyal, M. Hudson, K. Boutet, A. Serban, A. Masetto, M. Baron (2012)
High prevalence of occult left heart disease in scleroderma-pulmonary hypertensionEuropean Respiratory Journal, 42
G. Kovacs, H. Olschewski (2015)
Borderline pulmonary pressures in scleroderma - a ‘pre-pulmonary arterial hypertension’ condition?Arthritis Research & Therapy, 17
S. Mathai, L. Hummers, H. Champion, F. Wigley, A. Zaiman, P. Hassoun, R. Girgis (2009)
Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease.Arthritis and rheumatism, 60 2
S. Johnson, D. Patsios, D. Hwang, J. Granton (2006)
Pulmonary veno-occlusive disease and scleroderma associated pulmonary hypertension.The Journal of rheumatology, 33 11
C. Leroy, R. Altman, J. Kirsner, J. Myers, D. McShane, D. Masi, G. Sharp, G. Rodnan, A. MacKenzie-Graham, T. Medsger, J. Fries (1980)
Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.Arthritis and rheumatism, 23 5
A. Bohan, J. Peter (1975)
Polymyositis and dermatomyositis (first of two parts).The New England journal of medicine, 292 7
E. Tan, A. Cohen, J. Fries, A. Masi, D. McShane, N. Rothfield, J. Schaller, N. Talal, R. Winchester (1982)
The 1982 revised criteria for the classification of systemic lupus erythematosus.Arthritis and rheumatism, 25 11
R Kasukawa, T Tojo, S Miyawaki (1987)
Mixed connective tissue disease and antinuclear antibodies
A. Masi (1980)
Preliminary criteria for the classification of systemic sclerosis (scleroderma).Bulletin on the rheumatic diseases, 31 1
K. Tsuchida, H. Yamada, Y. Yamasaki, Kengo Suzuki, K. Kongoji, Y. Akashi, S. Ozaki (2015)
Left heart abnormalities in connective tissue disease patients with pre-capillary pulmonary hypertension as well as borderline mean pulmonary arterial pressureModern Rheumatology, 25
J. Avouac, P. Airó, C. Meune, L. Beretta, P. Dieudé, P. Caramaschi, K. Tiev, S. Cappelli, E. Diot, A. Vacca, J. Cracowski, J. Sibilia, A. Kahan, M. Matucci-Cerinic, Y. Allanore (2010)
Prevalence of Pulmonary Hypertension in Systemic Sclerosis in European Caucasians and Metaanalysis of 5 StudiesThe Journal of Rheumatology, 37
I. Anand, J. McMurray, J. Cohn, M. Konstam, T. Notter, K. Quitzau, F. Ruschitzka, T. Lüscher (2004)
Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trialThe Lancet, 364
G. Kovacs, R. Maier, E. Aberer, M. Brodmann, W. Graninger, X. Kqiku, S. Scheidl, N. Tröster, C. Hesse, L. Rubin, H. Olschewski (2012)
Pulmonary arterial hypertension therapy may be safe and effective in patients with systemic sclerosis and borderline pulmonary artery pressure.Arthritis and rheumatism, 64 4
A. Master (1968)
The Master two-step testAmerican Heart Journal, 75
To clarify whether patients with connective tissue disease (CTD)-associated borderline mean pulmonary artery pressure (mPAP) have distinctive hemodynamic characteristics from those with normal mPAP and whether pathogenesis is as heterogeneous as manifest pulmonary hypertension (PH). Seventy-five CTD patients who underwent right heart catheterization (RHC) from 2008 through 2016 were retrospectively analyzed. We compared between-group differences in clinical and hemodynamic findings: normal mPAP (n = 35), borderline mPAP (n = 15), and PH (n = 25). A therapeutic intervention trial based on RHC results was performed in nine patients. The values of tricuspid regurgitation pressure gradient (TRPG) in patients with borderline mPAP were comparable at rest but became higher after exercise compared to those with a normal mPAP (P = 0.01). Pulmonary artery wedge pressure in patients with borderline mPAP was higher than in those with normal mPAP (P < 0.0001) and comparable to those with PH. Each of the three patients was treated for pre-capillary and post-capillary disease and two for interstitial lung disease (ILD). During the mean follow-up period of 40 months, mPAP or TRPG normalized in all patients treated for pre-capillary and post-capillary disease. One patient with severe ILD developed to PH and died from it. CTD patients with borderline mPAP, the underlining pathogenesis of which is heterogeneous as PH, have distinctive hemodynamic characteristics from those with normal mPAP. Whether a specific treatment targeting the inflammatory process or local hemodynamics may alter the clinical course to PH is a topic for future research.
Clinical Rheumatology – Springer Journals
Published: May 18, 2018
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.